2. Academic Validation
  3. Pancreatic neuroendocrine tumors: Challenges in an underestimated disease

Pancreatic neuroendocrine tumors: Challenges in an underestimated disease

  • Crit Rev Oncol Hematol. 2016 May;101:193-206. doi: 10.1016/j.critrevonc.2016.03.013.
A Viúdez 1,  A De Jesus-Acosta 2,  F L Carvalho 3,  R Vera 4,  S Martín-Algarra 5,  N Ramírez 6
Affiliations

Affiliations

  • 1 Department of Medical Oncology, Complejo Hospitalario de Navarra, IdiSNA Navarra Institute for Health Research, Navarra Public Health System, Pamplona, Navarra, Spain. Electronic address: antoniovb76@gmail.com.
  • 2 Department of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
  • 3 Department of Urology, Georgetown University Hospital, Washington DC, USA.
  • 4 Department of Medical Oncology, Complejo Hospitalario de Navarra, IdiSNA Navarra Institute for Health Research, Navarra Public Health System, Pamplona, Navarra, Spain.
  • 5 Department of Medical Oncology, University Clinic of Navarra, University of Navarra, IdiSNA Navarra Institute for Health Research, Pamplona, Spain.
  • 6 Oncohematology Research Group, Navarrabiomed-Miguel Servet Foundation, IdiSNA Navarra Institute for Health Research, Navarra Public Health System, Pamplona, Navarra, Spain. Electronic address: nramireh@cfnavarra.es.
PMID: 27021395 DOI: 10.1016/j.critrevonc.2016.03.013
Abstract

Pancreatic neuroendocrine tumours (PanNETs) are considered a relatively unusual oncologic entity. Due to its relative good prognosis, surgery remains the goal standard therapy not only in localized disease but also in the setting of locally or metastatic disease. Most of the patients are diagnosed in metastatic scenario, where multidisciplinary approach based on surgery, chemotherapies, liver-directed and/or molecular targeted therapies are commonly used. Owing to a deeper molecular knowledge of this disease, these targeted therapies are nowadays widely implemented, being the likely discovery of predictive biomarkers that would allow its use in other settings. This review is focused on describing the different classifications, etiology, prognostic biomarkers and multidisciplinary approaches that are typically used in PanNET.

Keywords

Foregut; Gastrointestinal neuroendocrine tumors; Pancreas surgery; Pancreatic Neuroendocrine Tumor (PanNET); Targeted therapies.

Figures